|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Editorials |
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA (S.M.C., S.L.R, N.B., K.R.L.; Department of Oncology, Mayo Clinic Cancer Center; Rochester, MN 55905, USA (J.C.B.); National Cancer Research Network, Leeds LS16 6QB, UK (R.S.K.); Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA (D.D.B.)
1 Address correspondence to Susan M. Chang, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Ave., A 808, Box 0372, San Francisco, CA 94143-0372. (changs{at}neurosurg.ucsf.edu).
Abstract
We present guidelines to standardize the reporting of phase 1 and phase 2 neuro-oncology trials. The guidelines are also intended to assist with accurate interpretation of results from these trials, to facilitate the peer-review process, and to expedite the publication of important and accurate manuscripts. Our guidelines are summarized in a checklist format that can be used as a framework from which to construct a phase 1 or 2 clinical trial.
References
Ad Hoc Working Group for Critical Appraisal of the Medical Literature. (1987) A proposal for more informative abstracts of clinical articles. Ann. Intern. Med. 106, 598-604.
Altman, D.G., Schulz, K.F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gotzsche, P.C., and Lang, T. (2001) The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann. Intern. Med. 134, 663-694.
Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L.M., Moher, D., Rennie, D., de Vet, H.C., and Lijmer, J.G. (2003) The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Clin. Chem. 49, 7-18.
Cairncross, J.G., Macdonald, D.R., Pexman, J.H., and Ives, F.J. (1988) Ste roid-induced CT changes in patients with recurrent malignant glioma. Neurology 38, 724-726.
Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Jr., Spence, A.M., Berger, M.S., Mehta, M., Pollack, I.F., Rankin, C., and Prados, M.D. (2001) A Phase II study of paclitaxel in patients with recurrent malig nant glioma using different doses depending upon the concomitant use of anticonvulsants: A North American Brain Tumor Consortium report. Cancer 91, 417-422.[CrossRef][Web of Science][Medline]
Des Jarlais, D.C., Lyles, C., and Crepaz, N. (2004) Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. Am. J. Public Health 94, 361-366.
Haines, S.J. (2002) Moving targets and ghosts of the past: Outcome mea surement in brain tumour therapy. J. Clin. Neurosci. 9, 109-112.[CrossRef][Web of Science][Medline]
Haynes, R.B., Mulrow, C.D., Huth, E.J., Altman, D.G., and Gardner, M.J. (1990) More informative abstracts revisited. Ann. Intern. Med. 113, 69-76.
Hess, K.R., Wong, E.T., Jaeckle, K.A., Kyritsis, A.P., Levin, V.A., Prados, M.D., and Yung, W.K. (1999) Response and progression in recurrent malignant glioma. Neuro-Oncology 1, 282-288.[Abstract]
Irish, W.D., Macdonald, D.R., and Cairncross, J.G. (1997) Measuring bias in uncontrolled brain tumor trials—to randomize or not to randomize? Can. J. Neurol. Sci. 24, 307-312.[Web of Science][Medline]
Kirby, S., Brothers, M., Irish, W., Florell, R., Macdonald, D., Schold, C., and Cairncross, G. (1995) Evaluating glioma therapies: Modeling treatments and predicting outcomes. J. Natl. Cancer Inst. 87, 1884-1888.
Kleihues, P., and Ohgaki, H. (1999) Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-Oncology 1, 44-51.[Abstract]
Lamborn, K.R., Chang, S.M., and Prados, M.D. (2004) Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analy sis. Neuro-Oncology 6, 227-235.[Abstract]
Lee, J.J., and Feng, L. (2005) Randomized phase II designs in cancer clinical trials: Current status and future directions. J. Clin. Oncol. 23, 4450-4457.
Macdonald, D.R., Cascino, T.L., Schold, S.C., Jr., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280.[Abstract]
Mariani, L., and Marubini, E. (2000) Content and quality of currently pub lished phase II cancer trials. J. Clin. Oncol. 18, 429-436.
NCI (2003) Common Terminology Criteria for Adverse Events v.3.0. NCI Cancer Therapy Evaluation Program. Available at http://ctep.cancer.gov/reporting/ctc.html. Accessed May 15, 2005.
NCI (2005) Adverse Event Expedited Reporting System (AdEERS). NCI Cancer Therapy Evaluation Program. Available at http://ctep.cancer.gov/reporting/adeers.html. Accessed May 15, 2005.
Prados, M.D., Yung, W.K., Jaeckle, K.A., Robins, H.I., Mehta, M.P., Fine, H.A., Wen, P.Y., Cloughesy, T.F., Chang, S.M., Nicholas, M.K., Schiff, D., Greenberg, H.S., Junck, L., Fink, K.L., Hess, K.R., and Kuhn, J. (2004) Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-Oncology 6, 44-54.[Abstract]
Radner, H., Blumcke, I., Reifenberger, G., and Wiestler, O.D. (2002) [The new WHO classification of tumors of the nervous system 2000. Pathol ogy and genetics]. [German] Pathologe 23, 260-283.[CrossRef][Web of Science][Medline]
Scott, C.B., Nelson, J.S., Farnan, N.C., Curran, W.J., Jr., Murray, K.J., Fis chbach, A.J., Gaspar, L.E., and Nelson, D.F. (1995) Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02. Cancer 76, 307-313.[CrossRef][Web of Science][Medline]
Simon, R. (1989) Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1-10.[Web of Science][Medline]
Vecht, C.J., Wagner, G.L., and Wilms, E.B. (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2, 404-409.[CrossRef][Web of Science][Medline]
Wong, E.T., Hess, K.R., Gleason, M.J., Jaeckle, K.A., Kyritsis, A.P., Prados, M.D., Levin, V.A., and Yung, W.K. (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17, 2572-2578.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Zohar, Qing Lian, V. Levy, K. Cheung, A. Ivanova, and S. Chevret Quality assessment of phase I dose-finding cancer trials: proposal of a checklist Clinical Trials, October 1, 2008; 5(5): 478 - 485. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
